GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinovac Biotech Ltd (NAS:SVA) » Definitions » EV-to-Revenue

SVA (Sinovac Biotech) EV-to-Revenue : -16.15 (As of Jun. 27, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Sinovac Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Sinovac Biotech's enterprise value is $-6,932.0 Mil. Sinovac Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $429.2 Mil. Therefore, Sinovac Biotech's EV-to-Revenue for today is -16.15.

The historical rank and industry rank for Sinovac Biotech's EV-to-Revenue or its related term are showing as below:

SVA' s EV-to-Revenue Range Over the Past 10 Years
Min: -15.54   Med: 1.29   Max: 6.21
Current: -16.15

During the past 13 years, the highest EV-to-Revenue of Sinovac Biotech was 6.21. The lowest was -15.54. And the median was 1.29.

SVA's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 7.685 vs SVA: -16.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-27), Sinovac Biotech's stock price is $6.47. Sinovac Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $4.31. Therefore, Sinovac Biotech's PS Ratio for today is 1.50.


Sinovac Biotech EV-to-Revenue Historical Data

The historical data trend for Sinovac Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinovac Biotech EV-to-Revenue Chart

Sinovac Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.09 -0.05 -0.42 -4.56 -15.94

Sinovac Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -4.56 - -15.94 -

Competitive Comparison of Sinovac Biotech's EV-to-Revenue

For the Biotechnology subindustry, Sinovac Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinovac Biotech's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sinovac Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sinovac Biotech's EV-to-Revenue falls into.


;
;

Sinovac Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Sinovac Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-6931.952/429.204
=-16.15

Sinovac Biotech's current Enterprise Value is $-6,932.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinovac Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $429.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech  (NAS:SVA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Sinovac Biotech's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.47/4.308
=1.50

Sinovac Biotech's share price for today is $6.47.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was $4.31.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinovac Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sinovac Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinovac Biotech Business Description

Traded in Other Exchanges
N/A
Address
No.39, Shangdi Xi Road, Haidan District, Beijing, CHN, 100085
Sinovac Biotech Ltd is a China-based biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including, without limitation, hepatitis A, hepatitis B, hand foot and mouth disease (HFMD) caused by EV71, seasonal influenza, H5N1 and H1N1 pandemic influenza, coronavirus, pneumococcus, poliomyelitis, varicella and mumps.
Executives
Lily Wang director, 10 percent owner, officer: Chief Financial Officer 300 MURCHISON DR., MILLBRAE CA 94030
Ifg Investments Services Inc 10 percent owner PO BOX 822, CHARLESTOWN FEDERATION OF ST KITTS & NEVIS WEST INDIES P8 00000
Yin Weidong director, 10 percent owner, officer: President and CEO
Terry G Bowering director, 10 percent owner, officer: President, CEO 10 CEDAR MEADOW DRIVE REGINA A9 S4X 3J6